EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial

Marco Valgimigli iD, Adrian Wlodarczak, Ralph Tölg, Béla Merkely iD, Henning Kelbæk iD, Jacek Legutko iD, Stefano Galli, Matthieu Godin iD, Gabor G Toth iD, Thibault Lhermusier iD, Benjamin Honton, Peter Laurenz Dietrich iD und 6 weitere

Circulation · 2023

DOI: 10.1161/circulationaha.123.065448 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2023. Verfasst von Marco Valgimigli und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Università della Svizzera Italiana, Lugano, Switzerland (M.V.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents, Percutaneous Coronary Intervention, Myocardial Infarction. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotronik.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbreviated dual antiplatelet therapy duration after percutaneous coronary intervention (PCI). The aim of this study was to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-polymer zotarolimus-eluting stent in patients at high bleeding risk receiving 1 month of dual antiplatelet therapy after PCI. METHODS: The Bioflow-DAPT Study is an international, randomized, open-label trial conducted at 52 interventional cardiology hospitals in 18 countries from February 24, 2020, through September 20, 2021. Patients with a clinical indication to PCI because of acute or chronic coronary syndrome who fulfilled 1 or more criteria for high bleeding risk were eligible for enrollment. Patients were randomized to receive either biodegradable-polymer sirolimus-eluting stents or durable-polymer, slow-release zotarolimus-eluting stents after successful lesion preparation, followed by 1 month of dual antiplatelet therapy and thereafter single antiplatelet therapy. The primary outcome was the composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year, and was powered for noninferiority, with an absolute margin of 4.1% at 1-sided 5% alpha. RESULTS: A total of 1948 patients at high bleeding risk were randomly assigned (1:1) to receive biodegradable-polymer sirolimus-eluting stents (969 patients) or durable-polymer zotarolimus-eluting stents (979 patients). At 1 year, the primary outcome was observed in 33 of 969 patients (3.6%) in the biodegradable-polymer sirolimus-eluting stent group and in 32 of 979 patients (3.4%) in the durable-polymer zotarolimus-eluting stent group (risk difference, 0.2 percentage points; upper boundary of the 1-sided 95% CI, 1.8; upper boundary of the 1-sided 97.5% CI, 2.1; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseDrug-Eluting StentsPercutaneous Coronary InterventionMyocardial InfarctionThrombosisHumansEverolimusPolymersPlatelet Aggregation InhibitorsTreatment OutcomeAbsorbable ImplantsSirolimusStents

Stichwörter der Autor:innen

aspirindrug-eluting stentshemorrhagerisktherapeutics

Substanzen

zotarolimusEverolimusPolymersPlatelet Aggregation InhibitorsSirolimus

Autor:innen und Institutionen

  • Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Università della Svizzera Italiana, Lugano, Switzerland (M.V.).
  • Poland Miedziowe Centrum Zdrowia Lubin, Poland (A.W.).
  • Herzzentrum der Segeberger Kliniken GmbH, Bad Segeberg, Germany (R.T.).
  • Semmelweis University, Heart and Vascular Center, Budapest, Hungary (B.M.).
  • Department of Cardiology, Zealand University Hospital, Roskilde, Denmark (H.K.).
  • Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.L.).

ORCID-Profile: Marco Valgimigli, Béla Merkely, Henning Kelbæk, Jacek Legutko, Matthieu Godin, Gabor G Toth, Thibault Lhermusier, Peter Laurenz Dietrich, Johanne Silvain, Davide Capodanno, Guillaume Cayla

Förderung

  • Biotronik

Zitieren

APA

Valgimigli, M., Wlodarczak, A., Tölg, R., Merkely, B., Kelbæk, H., Legutko, J., Galli, S., Godin, M., Toth, G. G., Lhermusier, T., Honton, B., Dietrich, P. L., Stammen, F., Ferdinande, B., Silvain, J., Capodanno, D., Cayla, G., & Bioflow-DAPT Investigators (2023). Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial. Circulation. https://doi.org/10.1161/circulationaha.123.065448

Vancouver

Valgimigli M, Wlodarczak A, Tölg R, Merkely B, Kelbæk H, Legutko J, et al. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial. Circulation. 2023. doi:10.1161/circulationaha.123.065448

BibTeX
@article{Valgimigli2023,
  author = {Valgimigli, Marco and Wlodarczak, Adrian and Tölg, Ralph and Merkely, Béla and Kelbæk, Henning and Legutko, Jacek and Galli, Stefano and Godin, Matthieu and Toth, Gabor G and Lhermusier, Thibault and Honton, Benjamin and Dietrich, Peter Laurenz and Stammen, Francis and Ferdinande, Bert and Silvain, Johanne and Capodanno, Davide and Cayla, Guillaume and Bioflow-DAPT Investigators, Bioflow-DAPT Investigators},
  title = {Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial},
  journal = {Circulation},
  year = {2023},
  doi = {10.1161/circulationaha.123.065448}
}
Kostenlos starten →